Ovagen

Most Common Uses

Ovagen is a tripeptide bioregulator primarily used to support liver and gastrointestinal (GI) tract function. It is often employed in research and clinical settings to address conditions such as chronic hepatitis, liver fibrosis, and GI mucosal damage caused by antibiotics, environmental toxins, or chemotherapy.

Ovagen is also explored for its potential to normalize liver function in elderly individuals and as a preventative measure against complications from radiation, chemotherapy, or long-term antibiotic use. Additionally, there is interest in its ability to support metabolic processes and aid in detoxification, particularly in cases of malnutrition or exposure to adverse environmental factors.

Additionally, Ovagen shows promise as an HIV-1 protease inhibitor, potentially reducing the virus’s ability to replicate and survive.

Warnings and Cautions

Ovagen is generally well-tolerated with no significant side effects, complications, or contraindications reported in clinical studies. However, individuals with allergies to gelatin (used in capsule shells) or lactose should be careful. It also may cause a mild gastrointestinal discomfort in sensitive individuals.

Ovagen is not intended for human consumption outside of research settings, and its use should be supervised by qualified professionals. There is a risk of confusion with a similarly named product containing ovine follicle-stimulating hormone (FSH), which has entirely different functions. Researchers and users must ensure they are using the correct tripeptide bioregulator.

Dosages

Typical doses are individualized based on clinical evaluation, often administered in cycles depending on health needs and response. Ovagen is usually taken orally with the dosage ranging from 25 to 50 mg per pill. It is also available in the injectable form.

Mechanism of Action

Ovagen, a Khavinson peptide, is a tripeptide composed of glutamic acid, aspartic acid, and leucine (Glu-Asp-Leu, or EDL). It acts as a bioregulator by crossing cell and nuclear membranes to interact directly with DNA, influencing transcription patterns in a tissue-specific manner.

In the liver and GI tract, Ovagen promotes the normalization of cellular function by reducing DNA condensation, thereby enhancing gene expression to restore a more youthful, functional state. This process helps mitigate age-related cellular senescence, supporting liver cell regeneration, detoxification, and protein synthesis.

Ovagen also shows potential in protecting the GI mucosal layer and reducing fibrosis in the liver, possibly by modulating inflammatory pathways. Some studies suggest it may inhibit HIV replication, though the exact mechanism remains under investigation.

Structure and Pharmacology

Ovagen’s chemical structure is a tripeptide with the amino acid sequence Glu-Asp-Leu (EDL), with a molecular formula of C15H25N3O8 and a molecular weight of 375.37 g/mol (PubChem CID: 444128). Its small size allows it to penetrate cellular and nuclear membranes efficiently, enabling direct interaction with DNA.

Pharmacologically, Ovagen exhibits tissue-specific effects, primarily targeting hepatocytes and GI mucosal cells. It is stable when stored at -20°C and reconstituted with sterile water or a buffer for research use. Ovagen’s bioavailability is enhanced in synthetic forms (cytogenes), which act faster than natural peptide extracts but have a shorter duration of effect.

It is typically administered orally (capsules), sublingually (liquid), or via injection in research settings, with no significant drug dependence or toxicity reported.

History

Ovagen was developed by Dr. Vladimir Khavinson, a prominent Russian gerontologist, through the Saint Petersburg Institute of Bioregulation and Gerontology. Khavinson’s 40-year research into peptide bioregulators led to the identification of short peptides, like Ovagen, that mimic the active sites of larger polypeptides extracted from animal organs.

Introduced as part of the cytogene class of synthetic peptides, Ovagen emerged from studies in the late 20th century aimed at slowing aging and enhancing organ function.

Khavinson’s work, documented in over 775 publications and 196 patents, established Ovagen as a key peptide for liver and GI health, with its development tied to advancements in gerontology and regenerative medicine in Russia. It has since been marketed as a dietary supplement and research peptide globally.

Research & Clinical Trials on Ovagen

Ovagen for Liver and Kidney Health

Studies on Ovagen (EDL) have been conducted using renal cell cultures undergoing senescence, serving as a model for cellular aging. These investigations are part of broader research into peptide-DNA interactions, focusing on how short peptides regulate gene expression and protein synthesis. The EDL peptide’s effects were examined in vitro, providing insights into its potential role in modulating age-related cellular processes.

Ovagen (EDL) was found to regulate the expression of the p53 apoptosis marker in senescent renal cell cultures. The p53 protein is critical for programmed cell death (apoptosis) and is often upregulated during cellular aging.

The research indicates that EDL exhibits hepatoprotective effects, suggesting a protective role for the liver. A significant property of Ovagen (EDL) is its ability to bind to DNA. This characteristic is central to its regulatory effects, likely underpinning its capacity to influence gene expression, including the modulation of the p53 marker.

The findings suggest that short peptides like Ovagen (EDL) possess a broad spectrum of biological effects, primarily through regulating gene expression and protein synthesis. Researchers propose that these peptides could serve as physiologically active components in pharmaceutical products, particularly for regenerative therapies or as additives in cell culture media for studying age-related diseases.

Ovagen and HIV-1

The study concludes that Glu-Asp-Leu (EDL) is a potent, selective, and hydrophilic inhibitor of HIV-1 protease, with potential implications for regulating viral replication. However, its moderate Ki (50 µM) indicates it is less potent than modern HIV-1 protease inhibitors.

Ovagen Lingual in Agricultural Productivity

The conclusion section of the research paper states that different concentrations of Ovagen Lingual exert varying effects on the germination of the Tverskoy variety of common flax. This observation underscores the importance of carefully determining the appropriate application rate for such bioactive compounds.

The finding that higher concentrations did not offer additional benefits underscores the importance of precise dosage in the application of this peptide complex. The study contributes to the growing understanding of the role of short peptides as plant growth stimulators in agriculture.